These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 1277205

  • 1. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.
    Brock N.
    Cancer Treat Rep; 1976 Apr; 60(4):301-8. PubMed ID: 1277205
    [Abstract] [Full Text] [Related]

  • 2. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.
    Hohorst HJ, Draeger U, Peter G, Voelcker G.
    Cancer Treat Rep; 1976 Apr; 60(4):309-15. PubMed ID: 1277206
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes.
    Cox PJ, Phillips BJ, Thomas P.
    Cancer Treat Rep; 1976 Apr; 60(4):321-6. PubMed ID: 179712
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacologic studies with trophosphamide (Ixoten), a new oxazaphosphorineoxide].
    Brock N.
    Med Monatsschr; 1973 Sep; 27(9):390-4. PubMed ID: 4768197
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
    Low JE, Borch RF, Sladek NE.
    Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
    [Abstract] [Full Text] [Related]

  • 12. Alkylating properties of phosphoramide mustard.
    Colvin M, Brundrett RB, Kan MN, Jardine I, Fenselau C.
    Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171
    [Abstract] [Full Text] [Related]

  • 13. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
    Lelieveld P, van Putten LM.
    Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
    [Abstract] [Full Text] [Related]

  • 14. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
    Voelcker G, Wagner T, Hohorst HJ.
    Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
    [Abstract] [Full Text] [Related]

  • 15. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.
    Low JE, Borch RF, Sladek NE.
    Cancer Res; 1983 Dec; 43(12 Pt 1):5815-20. PubMed ID: 6640533
    [Abstract] [Full Text] [Related]

  • 16. Reactions of nitrogen mustards with DNA.
    Hemminki K, Kallama S.
    IARC Sci Publ; 1986 Dec; (78):55-70. PubMed ID: 3583398
    [Abstract] [Full Text] [Related]

  • 17. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.
    Jardine I, Brundrett R, Colvin M, Fenselau C.
    Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of neutrophil chemotaxis by 4-hydroxycyclophosphamide.
    Gilbert DN, Starr P, Eubanks N.
    Cancer Res; 1977 Feb; 37(2):456-9. PubMed ID: 832269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.